Experimental melanoma vaccine shows promise, but data details awaited

Scientists are reacting with a mix of excitement and caution to the preliminary results announced by Moderna and Merck for an experimental melanoma vaccine. The companies reported positive outcomes from a Phase III clinical trial, but details regarding survival rates and recurrence remain undisclosed.

The trial, named "INTerpath-001," involved 1,137 patients who had previously undergone surgery to remove melanoma. The study evaluated a combination therapy: Moderna's personalized mRNA-based "intismeran autogene" vaccine alongside Merck's immunotherapy drug pembrolizumab (Keytruda). The pharmaceutical companies stated that this combined approach demonstrated statistically significant and clinically relevant improvements in recurrence-free survival and distant metastasis-free survival compared to Keytruda used alone.

However, experts are emphasizing the need for more data. José Bautista, a molecular biology professor at Spain's Complutense University of Madrid, noted that the press releases offer an "interpretation" of the results rather than the raw clinical and scientific data required for independent verification. He highlighted the absence of statistical data comparing the two groups in the trial, one receiving the combination therapy and the other receiving Keytruda monotherapy.

Bautista suggested the companies' communication might be strategic, but acknowledged the significant scientific potential of the announcement. He pointed to positive early-phase trial results as a basis for this optimism. Lennard Lee, a senior clinical advisor on cancer vaccines at the University of Oxford, echoed this sentiment, calling the results encouraging but stressing the importance of waiting for complete data. Lee indicated that detailed subgroup analyses, quality-of-life data, and definitive overall survival results are crucial for understanding the treatment's full benefit and its potential place in standard melanoma care.